Icelanders, whose unusually low genetic variability makes them ideal for
studies on the origin of diseases, have agreed to reveal the secrets of their
genes to pharmaceuticals company Hoffmann-La Roche. The deal, worth $200
million, gives the company and its partner—deCode Genetics of
Reykjavik—exclusive rights to develop drugs from the genetic data of
Iceland’s population. In return, Icelanders will receive any resulting medicines
free.
More from New Scientist
Explore the latest news, articles and features
Environment
Galapagos corals suggest climate change drives stronger El Niños
News
Life
Astonishing whale feeding frenzy seen off the eastern coast of Greenland
News
Environment
Octopuses released into Adriatic Sea to tackle invasive crabs
News
Technology
Driving data can predict crash black spots before accidents happen
News
Popular articles
Trending New Scientist articles